Regenerative medicine for the cornea
J-TEC has made progress in the development of Autologous Cultured Oral Mucosal Epithelium for the treatment of patients with limbal stem cell deficiency that is difficult to treat with Autologous Cultured Corneal Epithelium because the cornea of both eyes has been damaged and corneal epithelial stem cells cannot be harvested from the patient's eyes. Autologous oral mucosal epithelium is a cell sheet of autologous oral mucosal epithelial origin, made by culturing the patient's own oral mucosal tissue. The aim is to repair that patient's corneal epithelium by transplanting autologous oral mucosal epithelium into the patient's eyes.
J-TEC has introduced technology developed by Osaka University and has moved forward with the development of autologous oral mucosal epithelium. We applied for marketing approval in September of 2020, and marketing approval was obtained for Autologous Cultured Oral Mucosal Epithelium in June, 2021.
Limbal stem cell deficiency treatments using Autologous Cultured Oral Mucosal Epithelium have been covered by insurance since December 1, 2021.
The use and commercialization of the medicinal products developed by Japan Tissue Engineering Co., Ltd. that are referred to on this website are approved only in Japan. A potential use and commercialization in other regions will be subject to the prior granting of a marketing authorization in the given territory and compliance with applicable laws.